Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil

被引：6
|
作者：
Tam, Constantine [1 ,2 ]
Kuss, Bryone [5 ,6 ]
Opat, Stephen [3 ,4 ]
Boulos, Joy [7 ]
Marlton, Paula [8 ,9 ]
机构：
[1] St Vincents Hosp, Dept Haematol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia
[3] Monash Med Ctr, Dept Haematol, Melbourne, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Flinders Univ S Australia, Dept Haematol, Adelaide, SA, Australia
[6] Flinders Med Ctr, Adelaide, SA, Australia
[7] Roche Prod Ltd, Sydney, NSW, Australia
[8] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld, Australia
[9] Univ Queensland, Sch Med, Brisbane, Qld, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2017年 / 47卷
关键词：
anti-CD20; monoclonal antibody; rituximab; obinutuzumab; CLL; ILLNESS RATING-SCALE; NON-HODGKIN-LYMPHOMA; RITUXIMAB; TRIAL; CLL; CYCLOPHOSPHAMIDE; FLUDARABINE; SURVIVAL; REGIMEN;
D O I：
10.1111/imj.13493
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with chronic lymphocytic leukaemia (CLL) are generally older, with many considered unfit' for fludarabine-cyclophosphamide-rituximab therapy. In these patients, the combination of obinutuzumab-chlorambucil may be an appropriate therapeutic choice. Obinutuzumab-chlorambucil has been demonstrated to improve overall survival rates compared to chlorambucil alone and to improve progression-free survival and overall response rates compared to rituximab-chlorambucil. This combination can lead to certain toxicities that need to be addressed through appropriate patient selection, pre-medication and management. In this paper, we discuss evidence-based and author-recommended practical management of first-line CLL patients receiving obinutuzumab-chlorambucil.
引用
收藏
页码：5 / 10
页数：6
相关论文
共 50 条
  • [21] Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study
    Stilgenbauer, Stephan
    Bosch, Francesc
    Ilhan, Osman
    Kisro, Jens
    Mahe, Beatrice
    Mikuskova, Eva
    Osmanov, Dzhelil
    Reda, Gianluigi
    Robinson, Sue
    Tausch, Eugen
    Turgut, Mehmet
    Wojtowicz, Marcin
    Boettcher, Sebastian
    Perretti, Thomas
    Trask, Peter
    Van Hoef, Marlies
    Leblond, Veronique
    Foa, Robin
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (02) : 325 - 338
  • [22] Elevate Tn Phase 3 Study of Acalabrutinib Plus Obinutuzumab or Acalabrutinib Monotherapy vs Chlorambucil Plus Obinutuzumab (ClbO) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Martens, Uwe
    Sharman, Jeff
    Banerji, Versha
    Fogliatto, Laura Maria
    Herishanus, Yair
    Munir, Talha
    Walewska, Renato
    Follows, George
    Karlsson, Karin
    Ghia, Paolo
    Corbett, Gillian
    Walker, Patricia
    Egyed, Miklos
    Jurczak, Wojciech
    Salles, Gilles
    Janssens, Ann
    Cymbalista, Florence
    Wierda, William
    Coutre, Steven E.
    Pagel, John M.
    Skarbnik, Alan P.
    Kamdar, Manali
    Izumi, Raquel
    Munugala, Veerendra
    Patel, Priti
    Wang, Min Hui
    Wong, Sofia
    Woyach, Jennifer
    Byrd, John
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 127 - 127
  • [23] Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
    Al-Sawaf, Othman
    Zhang, Can
    Tandon, Maneesh
    Sinha, Arijit
    Fink, Anna-Maria
    Robrecht, Sandra
    Samoylova, Olga
    Liberati, Anna M.
    Pinilla-Ibarz, Javier
    Opat, Stephen
    Sivcheva, Liliya
    Le Du, Katell
    Fogliatto, Laura M.
    Niemann, Carsten U.
    Weinkove, Robert
    Robinson, Sue
    Kipps, Thomas J.
    Tausch, Eugen
    Schary, William
    Ritgen, Matthias
    Wendtner, Clemens-Martin
    Kreuzer, Karl-Anton
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Hallek, Michael
    Fischer, Kirsten
    LANCET ONCOLOGY, 2020, 21 (09): : 1188 - 1200
  • [24] Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia
    Sharman, Jeff P.
    Burke, John M.
    Yimer, Habte A.
    Boxer, Michael A.
    Babu, Sunil
    Li, Jia
    Mun, Yong
    Danilov, Alexey V.
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 791 - 800
  • [25] Cost‐Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy
    Ana Teresa Paquete
    Luís Silva Miguel
    Ursula Becker
    Catarina Pereira
    Carlos Gouveia Pinto
    Applied Health Economics and Health Policy, 2017, 15 : 501 - 512
  • [26] Obinutuzumab and Chlorambucil Versus Chlorambucil Monotherapy for Treatment of Previously Untreated Chronic Lymphocytic Leukemia Where Fludarabine-Based Chemotherapy Is Considered Inappropriate: A Canadian Cost-Utility Analysis
    Cameron, Heather
    Thompson, Melissa
    Marino, John-Paul
    Duong, Michael
    Becker, Ursula
    Wiesner, Christof
    BLOOD, 2014, 124 (21)
  • [27] Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
    Byrd, John C.
    Flynn, Joseph M.
    Kipps, Thomas J.
    Boxer, Michael
    Kolibaba, Kathryn S.
    Carlile, David J.
    Fingerle-Rowson, Guenter
    Tyson, Nicola
    Hirata, Jamie
    Sharman, Jeff P.
    BLOOD, 2016, 127 (01) : 79 - 86
  • [28] An updated survival analysis from the CLL11 study in patients with chronic lymphocytic leukaemia treated with obinutuzumab or rituximab in combination with chlorambucil versus chlorambucil alone
    Follows, G.
    Fischer, K.
    Bosch, F.
    Frederiksen, H.
    Cuneo, A.
    Ludwig, H.
    Crompton, N.
    Maurer, J.
    Uguen, M.
    Fingerle-Rowson, G.
    Hallek, M.
    Goede, V.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 95 - 95
  • [29] Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
    Visentin, Andrea
    Mauro, Francesca Romana
    Catania, Gioachino
    Fresa, Alberto
    Vitale, Candida
    Sanna, Alessandro
    Mattiello, Veronica
    Cibien, Francesca
    Sportoletti, Paolo
    Gentile, Massimo
    Rigolin, Gian Matteo
    Quaglia, Francesca Maria
    Murru, Roberta
    Gozzetti, Alessandro
    Molica, Stefano
    Marchetti, Monia
    Pravato, Stefano
    Angotzi, Francesco
    Cellini, Alessandro
    Scarfo, Lydia
    Reda, Gianluigi
    Coscia, Marta
    Laurenti, Luca
    Ghia, Paolo
    Foa, Robin
    Cuneo, Antonio
    Trentin, Livio
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Single Hospital Retrospective Review of Obinutuzumab and Chlorambucil combination therapy in patients with untreated Chronic Lymphatic Leukaemia in a District General Hospital (DGH)
    Owen, S.
    Kundu, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 182 - 182
12345